http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2022035914-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f4b33848df6489a50220606b5b5f049 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1157 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1114 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1164 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2502-1107 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0668 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0665 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0775 |
| filingDate | 2020-10-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c1f2a11499e63a90cf0355fc229d5679 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44254f2e73241f3b96c58211e43e0fda http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30f7c89665cef95fbc4a4ee5e4545a09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_69f8150b37ce8fd41281acc1d090af45 |
| publicationDate | 2022-03-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2022035914-A |
| titleOfInvention | Fast and Efficient In Vitro Amplification Human Mesenchymal Stem Cell Methods and Uses |
| abstract | PROBLEM TO BE SOLVED: To provide a method for in vitro amplification of human mesenchymal stem cells at high speed and efficiently. By co-culturing immune cells in human peripheral blood and human mesenchymal stem cells at a specific cell ratio, the proliferative capacity of human mesenchymal stem cells is significantly improved, and the in vitro amplification number thereof is usually high. More than 10 times the method, and the amplified cells maintain the biological properties of stem cells, with stronger self-renewal and multi-directional differentiation potential. Human peripheral blood immune cells derived from donors of different ages have no difference in proliferative effect on human mesenchymal stem cells and are not age-limited. Subjects can avoid the risk of immune rejection by amplifying human mesenchymal stem cells using their own peripheral blood immune cells. By transplanting and treating the disease model using the cells amplified in the present invention, immune rejection does not occur. INDUSTRIAL APPLICABILITY The present invention effectively solves problems such as the number, quality, and therapeutic effect of stem cells for clinical application. [Selection diagram] FIG. 5 |
| priorityDate | 2020-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 275.